Healthcare One Bright Spot Amid EU Firms’ China Pessimism
This article was originally published in PharmAsia News
Executive Summary
As the Chinese economic slowdown worsens, pessimism about growth and profitability is prompting foreign businesses to reconsider their strategies in the country, with around one in four European companies planning layoffs. But while market access issues are hitting EU healthcare firms, there is more optimism in this sector, notes a new survey of business sentiment.
You may also be interested in...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.